Session

PP 05 IBD (Posters)

THIOPURINES EXPOSURE IN-UTERO IS NOT ASSOCIATED WITH ABNORMAL HAEMATOLOGIC AND BIOCHEMICAL PARAMETERS IN INFANTS: A PICCOLO-X STUDY
THIOPURINES EXPOSURE IN-UTERO IS NOT ASSOCIATED WITH ABNORMAL HAEMATOLOGIC AND BIOCHEMICAL PARAMETERS IN INFANTS: A PICCOLO-X STUDY

PP 05 IBD (Posters)  et al.

COMPARATIVE EFFICACY OF SECOND-LINE THERAPIES IN ULCERATIVE COLITIS: A MONOCENTRIC EXPERIENCE FROM A TERTIARY REFERRAL CENTER
COMPARATIVE EFFICACY OF SECOND-LINE THERAPIES IN ULCERATIVE COLITIS: A MONOCENTRIC EXPERIENCE FROM A TERTIARY REFERRAL CENTER

PP 05 IBD (Posters)  et al.

PREDICTIVE FACTORS ASSOCIATED WITH LONG-TERM SURVIVAL OF ANTI-TNF AGENTS IN THE MANAGEMENT OF CROHN’S DISEASE
PREDICTIVE FACTORS ASSOCIATED WITH LONG-TERM SURVIVAL OF ANTI-TNF AGENTS IN THE MANAGEMENT OF CROHN’S DISEASE

PP 05 IBD (Posters)  et al.

THE BURDEN OF BOWEL URGENCY IN ULCERATIVE COLITIS: A FRENCH MULTICENTRIC REAL-LIFE STUDY (THEFAR)
THE BURDEN OF BOWEL URGENCY IN ULCERATIVE COLITIS: A FRENCH MULTICENTRIC REAL-LIFE STUDY (THEFAR)

PP 05 IBD (Posters)  et al.

FATIGUE IS NOT RELATED TO SARCOPENIA IN CROHN'S DISEASE PATIENTS IN DEEP REMISSION
FATIGUE IS NOT RELATED TO SARCOPENIA IN CROHN'S DISEASE PATIENTS IN DEEP REMISSION

PP 05 IBD (Posters)  et al.

TARGET ENGAGEMENT AND PHARMACODYNAMIC MOLECULAR MECHANISM EVALUATION IN A PHASE 1B STUDY OF THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 IN ULCERATIVE COLITIS
TARGET ENGAGEMENT AND PHARMACODYNAMIC MOLECULAR MECHANISM EVALUATION IN A PHASE 1B STUDY OF THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 IN ULCERATIVE COLITIS

PP 05 IBD (Posters)  et al.

THE ASSOCIATION OF ENDOSCOPIC AND HISTOLOGIC ENDPOINTS WITH FAECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB
THE ASSOCIATION OF ENDOSCOPIC AND HISTOLOGIC ENDPOINTS WITH FAECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB

PP 05 IBD (Posters)  et al.

COMBINING LEUCINE-RICH ALPHA-2 GLYCOPROTEIN AND FAECAL BIOMARKERS FOR ACCURATE MONITORING OF SMALL BOWEL ACTIVITY IN CROHN’S DISEASE
COMBINING LEUCINE-RICH ALPHA-2 GLYCOPROTEIN AND FAECAL BIOMARKERS FOR ACCURATE MONITORING OF SMALL BOWEL ACTIVITY IN CROHN’S DISEASE

PP 05 IBD (Posters)  et al.

COMPARATIVE EFFICACY AND SAFETY OF BIOLOGIC THERAPIES IN ELDERLY AND YOUNGER PATIENTS WITH INFLAMMATORY BOWEL DISEASE
COMPARATIVE EFFICACY AND SAFETY OF BIOLOGIC THERAPIES IN ELDERLY AND YOUNGER PATIENTS WITH INFLAMMATORY BOWEL DISEASE

PP 05 IBD (Posters)  et al.

TRANSMURAL HEALING IS NOT ASSOCIATED WITH LESS DISABILITY THAN COMPLETE ENDOSCOPIC MUCOSAL HEALING: A PROSPECTIVE STUDY IN CROHN'S DISEASE PATIENT
TRANSMURAL HEALING IS NOT ASSOCIATED WITH LESS DISABILITY THAN COMPLETE ENDOSCOPIC MUCOSAL HEALING: A PROSPECTIVE STUDY IN CROHN'S DISEASE PATIENT

PP 05 IBD (Posters)  et al.

HEALTH-RELATED QUALITY OF LIFE FROM THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE AMONG PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR AND CONCOMITANT THERAPIES: RESULTS FROM THE ETRASIMOD ELEVATE UC CLINICAL PROGRAMME
HEALTH-RELATED QUALITY OF LIFE FROM THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE AMONG PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY PRIOR AND CONCOMITANT THERAPIES: RESULTS FROM THE ETRASIMOD ELEVATE UC CLINICAL PROGRAMME

PP 05 IBD (Posters)  et al.

A SINGLE CENTRE AUDIT REVIEWING THE PRACTICE OF ACUTE SEVERE ULCERATIVE COLITIS (ASUC) MANAGEMENT USING CALCINEURIN INHIBITOR AND BIOLOGICAL THERAPY. ARE THEY SHOWING GOOD OUTCOME AND SUCCESS IN AVOIDING COLECTOMY AT 30 DAYS AND 1 YEAR MARK?
A SINGLE CENTRE AUDIT REVIEWING THE PRACTICE OF ACUTE SEVERE ULCERATIVE COLITIS (ASUC) MANAGEMENT USING CALCINEURIN INHIBITOR AND BIOLOGICAL THERAPY. ARE THEY SHOWING GOOD OUTCOME AND SUCCESS IN AVOIDING COLECTOMY AT 30 DAYS AND 1 YEAR MARK?

PP 05 IBD (Posters)  et al.

ULTRASOUND IS EFFECTIVE TO IDENTIFY MUCOSAL HEALING IN CROHN'S DISEASE PATIENTS : RESULTS OF A CROSS-SECTIONAL STUDY
ULTRASOUND IS EFFECTIVE TO IDENTIFY MUCOSAL HEALING IN CROHN'S DISEASE PATIENTS : RESULTS OF A CROSS-SECTIONAL STUDY

PP 05 IBD (Posters)  et al.

PREDICTORS OF ILLNESS TRAJECTORY IN NEWLY DIAGNOSED ULCERATIVE COLITIS: A 3-YEAR FOLLOW-UP COHORT STUDY
PREDICTORS OF ILLNESS TRAJECTORY IN NEWLY DIAGNOSED ULCERATIVE COLITIS: A 3-YEAR FOLLOW-UP COHORT STUDY

PP 05 IBD (Posters)  et al.

IMPACT OF ETRASIMOD ON BLOOD PRESSURE AND HYPERTENSION: DATA FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME
IMPACT OF ETRASIMOD ON BLOOD PRESSURE AND HYPERTENSION: DATA FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME

PP 05 IBD (Posters)  et al.

ENDOCANNABINOID SYSTEM IN INFLAMMATORY BOWEL DISEASES: MUCOSAL GENE EXPRESSION PRELIMINARY DATA
ENDOCANNABINOID SYSTEM IN INFLAMMATORY BOWEL DISEASES: MUCOSAL GENE EXPRESSION PRELIMINARY DATA

PP 05 IBD (Posters)  et al.

MATCHING-ADJUSTED INDIRECT COMPARISON OF UPADACITINIB VERSUS USTEKINUMAB ON ENDOSCOPIC OUTCOMES AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
MATCHING-ADJUSTED INDIRECT COMPARISON OF UPADACITINIB VERSUS USTEKINUMAB ON ENDOSCOPIC OUTCOMES AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

PP 05 IBD (Posters)  et al.

CIRCULATING MIRNAS IN INFLAMMATORY BOWEL DISEASES - PRELIMINARY RESULTS
CIRCULATING MIRNAS IN INFLAMMATORY BOWEL DISEASES - PRELIMINARY RESULTS

PP 05 IBD (Posters)  et al.

INTESTINAL ULTRASOUND COMBINED TO FECAL CALPROTECTIN IS EFFECTIVE TO PREDICT ENDOSCOPIC MUCOSAL HEALING IN ULCERATIVE COLITIS: A CROSS-SECTIONAL STUDY
INTESTINAL ULTRASOUND COMBINED TO FECAL CALPROTECTIN IS EFFECTIVE TO PREDICT ENDOSCOPIC MUCOSAL HEALING IN ULCERATIVE COLITIS: A CROSS-SECTIONAL STUDY

PP 05 IBD (Posters)  et al.

SAFETY OF VEDOLIZUMAB, USTEKINUMAB AND TNF INHIBITORS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE MONOCENTRIC COHORT STUDY
SAFETY OF VEDOLIZUMAB, USTEKINUMAB AND TNF INHIBITORS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE MONOCENTRIC COHORT STUDY

PP 05 IBD (Posters)  et al.

Item 181 - 200 / 826
1 2 3 4 5 6 7 8 9
10
11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42